Page 9 - Interim Analysis News Today

13.01.2022 Imcyse SA: Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study | Imcyse SA | News | Nachricht | Mitteilung

The fourth one, as they say, is the charm — will you need to receive a fourth COVID-19 vaccine this New Year 2021?

Interim analysis, from pfizer a couple weeks ago. 89%. then wait for the final analysis and hope its as good as it was in the interim and it was. the fact its a pill, can take at home is a game-changer. the others have to be infused, injected. 70% efficacy pt its not about supply. administering them. need infusion centers, nurses. like tamiflu. positive test, prescription, stay at home take it and prevent severe disease. >> is ittals a about willingness to take it? right? when i think about whos...

People with moderate or mild haemophilia A have significant unmet clinical needs, as this population may not use preventative treatments due to missed or delayed diagnoses of bleeding episodes and a lack

Phase III POLARIX trial showed Polivy plus R-CHP was the first treatment in two decades to significantly improve outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL) versus the standard of

/PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that data from clinical and non-clinical studies of Endo Aesthetics Qwo® (collagenase...

An experimental antiviral pill appears to work very well at keeping people who are at high risk of severe COVID-19 from being admitted to the hospital and dying, according to the drugs maker, Pfizer.

Press release content from Business Wire. The AP news staff was not involved in its creation.

Several presentations will highlight broad potential of CD19-targeted ADC ZYNLONTA (loncastuximab tesirine-lpyl) as a single agent and in combination for the treatment of non-Hodgkin lymphomas ADC

KEYTRUDA Continued To Improve Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB or IIC Melanoma at 2 nd Interim Analysis of Phase 3 KEYNOTE-716 Trial Exploratory 7-Year Follow-Up Data for KEYTRUDA in Advanced Melanoma Showed 38% of Patients Treated With KEYTRUDA Were Alive at 7 Years Merck known as MSD outside the United States and Canada, today announced new data ...